Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia

This nonrandomized controlled trial assesses safety and vision outcomes of gene therapy for patients with achromatopsia.

[1]  Terence R Flotte,et al.  Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? , 2019, Annual review of virology.

[2]  V. Sothilingam,et al.  Development of Methodology and Study Protocol: Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients with CNGA3-Linked Achromatopsia Investigated in an Exploratory Dose-Escalation Trial. , 2018, Human gene therapy. Clinical development.

[3]  M. Simunovic,et al.  Colour discrimination ellipses in choroideremia , 2018, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  M. Michaelides,et al.  Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options , 2018, Ophthalmic genetics.

[5]  B. Wilhelm,et al.  AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  B. Wilhelm,et al.  Superior Retinal Gene Transfer and Biodistribution Profile of Subretinal Versus Intravitreal Delivery of AAV8 in Nonhuman Primates. , 2017, Investigative ophthalmology & visual science.

[7]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[8]  Martin Biel,et al.  Subretinal Injection for Gene Therapy Does Not Cause Clinically Significant Outer Nuclear Layer Thinning in Normal Primate Foveae. , 2017, Investigative ophthalmology & visual science.

[9]  M. Seeliger,et al.  How do patients rate their subjective symptoms after CNGA3 gene therapy: First application of the instrument A3-PRO , 2017 .

[10]  Gislin Dagnelie,et al.  Development of the Ultra-Low Vision Visual Functioning Questionnaire (ULV-VFQ) , 2017, Translational vision science & technology.

[11]  E. Zrenner,et al.  The Clinical Phenotype of CNGA3-Related Achromatopsia: Pretreatment Characterization in Preparation of a Gene Replacement Therapy Trial. , 2017, Investigative ophthalmology & visual science.

[12]  B. Wilhelm,et al.  Development of a Chromatic Pupillography Protocol for the First Gene Therapy Trial in Patients With CNGA3-Linked Achromatopsia. , 2017, Investigative ophthalmology & visual science.

[13]  W. Hauswirth,et al.  Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia. , 2016, Human gene therapy. Clinical development.

[14]  C. Klaver,et al.  Causes and consequences of inherited cone disorders , 2014, Progress in Retinal and Eye Research.

[15]  R. MacLaren,et al.  Evaluation of an Optimized Injection System for Retinal Gene Therapy in Human Patients. , 2014, Human gene therapy methods.

[16]  Thomas Euler,et al.  A Tale of Two Retinal Domains: Near-Optimal Sampling of Achromatic Contrasts in Natural Scenes through Asymmetric Photoreceptor Distribution , 2013, Neuron.

[17]  Kathleen A. Marshall,et al.  AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness , 2012, Science Translational Medicine.

[18]  Michael J. Castle,et al.  Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.

[19]  C. Klaver,et al.  Progressive loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography. , 2010, Investigative ophthalmology & visual science.

[20]  N. Tanimoto,et al.  Restoration of cone vision in the CNGA3-/- mouse model of congenital complete lack of cone photoreceptor function. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  J. Keeffe,et al.  The psychometric validity of the NEI VFQ-25 for use in a low-vision population. , 2010, Investigative ophthalmology & visual science.

[22]  Timothy Edward John Behrens,et al.  Training induces changes in white matter architecture , 2009, Nature Neuroscience.

[23]  F. Ferris,et al.  Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. , 2008, Investigative ophthalmology & visual science.

[24]  P. Sieving,et al.  CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia , 2005, European Journal of Human Genetics.

[25]  R. Klein,et al.  Methods for the in vitro determination of an individual disposition towards TH1‐ or TH2‐reactivity by the application of appropriate stimulatory antigens , 2003, Clinical and experimental immunology.

[26]  C. Craft,et al.  Retinoic acid upregulates cone arrestin expression in retinoblastoma cells through a Cis element in the distal promoter region. , 2002, Investigative ophthalmology & visual science.

[27]  Herbert Jägle,et al.  Reorganization of human cortical maps caused by inherited photoreceptor abnormalities , 2002, Nature Neuroscience.

[28]  F. Müller,et al.  Cloning, Chromosomal Localization and Functional Expression of the Gene Encoding the α‐Subunit of the cG‐MP‐Gated Channel in Human Cone Photoreceptors , 1997, The European journal of neuroscience.

[29]  R. Samulski,et al.  A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication , 1987, Journal of virology.

[30]  D. Hubel,et al.  SINGLE-CELL RESPONSES IN STRIATE CORTEX OF KITTENS DEPRIVED OF VISION IN ONE EYE. , 1963, Journal of neurophysiology.

[31]  H R Blackwell,et al.  Rod and cone receptor mechanisms in typical and atypical congenital achromatopsia , 1961 .

[32]  Christopher S. Langlo,et al.  Retinal structure and function in achromatopsia: implications for gene therapy. , 2014, Ophthalmology.

[33]  S. Colan.  The why and how of Z scores. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.